Cardiff Oncology saw its shares nosedive following the departure of its CEO and CFO, plus questions about some Phase II data for its candidate onvansertib in first-line RAS-mutated metastatic ...
Prior seasonal influenza virus immunity did not impair antibody responses or protection conferred by the intranasal H5N1 vaccine.